You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-19-022: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-10-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Purpose Digital dentistry uses advanced materials and powerful manufacturing technologies aided by 3D imaging and processing software algorithms to produce dental devices and perform complex dental procedures. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delive ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAS-19-316 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    SBIRPhase I/Phase IIDepartment of Health and Human Services
  3. 2A: Air monitoring technology for air toxics

    Release Date: 06-16-2021Open Date: 06-16-2021Due Date: 08-03-2021Close Date: 08-03-2021

    New measurement technologies that can identify and quantify air toxic emissions. Technologies should provide real time, continuous measurements of concentrations with minimum detection limits below background concentrations or health risk-based thresholds. Additionally, new technology must be able to distinguish targets from potential interfering compounds. Technologies that can be used to detect ...

    SBIRPhase IEnvironmental Protection Agency
  4. 2F: Air monitoring technology for methane (CH4) from oil and gas storage tanks

    Release Date: 06-16-2021Open Date: 06-16-2021Due Date: 08-03-2021Close Date: 08-03-2021

    New measurement technologies that address these challenges and provide continuous quantitative CH4 emission rates (e.g. over timeframes of hours or days) to increase the number of tank measurement data points available across production sites, which will improve characterization of this emission source. In addition, as CH4 leaks from storage tanks coincide with the release of additional volatile o ...

    SBIRPhase IEnvironmental Protection Agency
  5. 2: Air Quality

    Release Date: 06-16-2021Open Date: 06-16-2021Due Date: 08-03-2021Close Date: 08-03-2021

    Air monitoring technology for air toxics Low-cost sensors for air toxics and odors Continuous Emission Monitoring System for metal HAPs Integrated sampling, continuous monitoring approaches for metal HAP emissions Innovations in technologies and strategie ...

    SBIRPhase IEnvironmental Protection Agency
  6. 3A: Air treatment technologies to reduce the risks from transmission of viruses and bacteria in enclosed or semi-enclosed environments

    Release Date: 06-16-2021Open Date: 06-16-2021Due Date: 08-03-2021Close Date: 08-03-2021

    Development of EPA-registered products or FIFRA-regulated devices that can be operated safely and continuously in occupied spaces and inactivate pathogens in the air (and ideally on surfaces). These technologies must be scalable and could be deployed/installed either in-room or in-duct (in HVAC systems).

    SBIRPhase IEnvironmental Protection Agency
  7. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-20-111: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-02-2020Open Date: 07-11-2020 Due Dates: Multiple Close Date: 05-08-2023

    A. Overview Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food a ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government